目的：本研究探讨荧光原位杂交技术（FISH）在甲磺酸伊马替尼（IM）治疗慢性粒细胞性白血病（CML）长期预后中的早期预测价值。方法选取60例 IM治疗阶段的 CML 患者骨髓标本，运用骨髓细胞形态学（BM）、FISH、逆转录-聚合酶链反应（RT-PCR）以及常规染色体分析方法（CC）对入组的 CML 患者每3～6个月进行48个月疗效观察。结果运用 FISH 技术在第3个月、第6个月以及第12个月检测融合基因 Bcr-abl 阳性细胞＜10％的病例，其在第12个月具有较高的细胞遗传学完全缓解（CCR），同时，在第36个月和第48个月所观察的大多数患者均获得了无事件生存，与 Bcr-abl 阳性细胞百分数＞10％的患者组比较，差异具有统计学意义（P ＜0．05）。相似的，运用 RT-PCR 和 CC 在第3个月和第6个月检测 Bcr-Abl mRNA 以及阳性分裂相百分数，两组病例在第36个月和第48个月的无事件生存率（EFS）差异无统计学意义（P ＞0．05），仅在第12个月差异具有统计学意义（P ＜0．05）。结论FISH 分析技术可以为 CML 的长期预后提供早期有效的预测。%Objective To investigate the early predictive significance of fluorescence in-situ hybridization (FISH) in the long-term prognosis of treating chronic myeloid leukemia(CML)by imatinib(IM).Methods A total of 60 patients with CML undergoing IMtreatment were enrolled,their bone marrow specimens were collected,and they were observed per 3-6 months for 48 months for treatment efficiency by bone marrow cell morphology(BM),FISH,reverse transcription polymerase chain reaction (RT-PCR)and karyotyping (CC).Results Applying FISH to detect the patients showed that BCR-ABL positive cell <1 0% in the 3rd month,the 6th month and the 1 2th month,which there was high CCR in the 1 2th month,and the most patients got free-event survival in the 36th and 48th months.Comparing with those whose BCR-ABL positive cell >1 0%,there was statistical significance (P <0.05).Similarly,applying RT-PCR and CC to detect Bcr-Abl mRNA and positive mitosis phase,there was no statistical difference in the 36th and 48th months(P >0.05),and there was statistical significance only in the 1 2th month (P <0.05).Conclusions FISH is able to provide the early and effective prediction for the long-term prognosis of CML.
展开▼
